NCT03781063: An ongoing trial by Sermonix Pharmaceuticals Inc.
This trial is ongoing. It must report results 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03781063 |
|---|---|
| Title | An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 20, 2019 |
| Completion date | May 8, 2025 |
| Required reporting date | May 8, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |